{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T03:24:33Z","timestamp":1771298673216,"version":"3.50.1"},"reference-count":29,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,4]]},"DOI":"10.1097\/ijg.0b013e31818fb434","type":"journal-article","created":{"date-parts":[[2009,5,21]],"date-time":"2009-05-21T19:08:39Z","timestamp":1242932919000},"page":"293-300","source":"Crossref","is-referenced-by-count":46,"title":["The Safety and Efficacy of Brinzolamide 1%\/Timolol 0.5% Fixed Combination Versus Dorzolamide 2%\/Timolol 0.5% in Patients With Open-angle Glaucoma or Ocular Hypertension"],"prefix":"10.1097","volume":"18","author":[{"given":"Gianluca","family":"Manni","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Phillipe","family":"Denis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Chew","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabeth D.","family":"Sharpe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Orengo-Nania","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael A.","family":"Coote","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guna","family":"Laganovska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lasma","family":"Volksone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thierry","family":"Zeyen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabella","family":"Filatori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"James","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tin","family":"Aung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-6-20210208","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1136\/bjo.2005.081224","article-title":"The number of people with glaucoma worldwide in 2010 and 2020","volume":"90","author":"Quigley","year":"2006","journal-title":"Br J Ophthalmol"},{"key":"R3-6-20210208","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1001\/archopht.121.1.48","article-title":"Factors for glaucoma progression and the effect of treatment: the early manifest glaucoma trial","volume":"121","author":"Leske","year":"2003","journal-title":"Arch Ophthalmol"},{"key":"R4-6-20210208","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1016\/j.ophtha.2007.03.016","article-title":"Predictors of long-term progression in the Early Manifest Glaucoma Trial","volume":"114","author":"Leske","year":"2007","journal-title":"Ophthalmology"},{"key":"R6-6-20210208","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1001\/archopht.120.6.701","article-title":"The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma","volume":"120","author":"Kass","year":"2002","journal-title":"Arch Ophthalmol"},{"key":"R7-6-20210208","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1001\/archopht.120.10.1268","article-title":"Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial","volume":"120","author":"Heijl","year":"2002","journal-title":"Arch Ophthalmol"},{"key":"R8-6-20210208","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/S0002-9394(98)00272-4","article-title":"The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma","volume":"126","year":"1998","journal-title":"Am J Ophthalmol"},{"key":"R9-6-20210208","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1097\/00061198-200310000-00001","article-title":"Compliance barriers in glaucoma: a systematic classification","volume":"12","author":"Tsai","year":"2003","journal-title":"J Glaucoma"},{"key":"R10-6-20210208","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.ophtha.2004.12.026","article-title":"Does adjunctive glaucoma therapy affect adherence to the initial primary therapy?","volume":"112","author":"Robin","year":"2005","journal-title":"Ophthalmology"},{"key":"R11-6-20210208","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.ajo.2007.06.012","article-title":"Adherence in glaucoma: objective measurements of once-daily and adjunctive medication use","volume":"144","author":"Robin","year":"2007","journal-title":"Am J Ophthalmol"},{"key":"R12-6-20210208","doi-asserted-by":"crossref","first-page":"1.e1","DOI":"10.1016\/j.ajo.2005.02.043","article-title":"The safety and efficacy of Travoprost 0.004%\/timolol 0.5% fixed combination ophthalmic solution","volume":"140","author":"Barnebey","year":"2005","journal-title":"Am J Ophthalmol"},{"key":"R13-6-20210208","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1076\/0271-3683(200002)2021-DFT085","article-title":"Toxicity of preserved antiglaucoma topical drugs in an in vitro model of conjunctival cells","volume":"20","author":"De Saint Jean","year":"2000","journal-title":"Curr Eye Res"},{"key":"R14-6-20210208","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1097\/00055735-200404000-00013","article-title":"Fixed combinations of topical glaucoma medications","volume":"15","author":"Fechtner","year":"2004","journal-title":"Curr Opin Ophthalmol"},{"issue":"2","key":"R15-6-20210208","doi-asserted-by":"crossref","first-page":"S119","DOI":"10.1016\/S0039-6257(99)00108-3","article-title":"Preclinical overview of brinzolamide","volume":"44","author":"DeSantis","year":"2000","journal-title":"Surv Ophthalmol"},{"key":"R16-6-20210208","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1016\/S0161-6420(83)34380-3","article-title":"The mechanism of betaxolol, a new ocular hypotensive agent","volume":"90","author":"Reiss","year":"1983","journal-title":"Ophthalmology"},{"key":"R17-6-20210208","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/S0149-2918(00)83063-5","article-title":"Patients' acceptance of a switch from dorzolamide to brinzolamide for the treatment of glaucoma in a clinical practice setting","volume":"22","author":"Barnebey","year":"2000","journal-title":"Clin Ther"},{"key":"R18-6-20210208","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1016\/S0161-6420(98)91046-6","article-title":"A randomized trial comparing the dorzolamide-timolol combination given twice daily to monotherapy with timolol and dorzolamide. Dorzolamide-Timolol Study Group","volume":"105","author":"Boyle","year":"1998","journal-title":"Ophthalmology"},{"key":"R19-6-20210208","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1159\/000027290","article-title":"Fluctuation of intraocular pressure during the day in open angle glaucoma, normal-tension glaucoma and normal subject","volume":"212","author":"Sacca","year":"1998","journal-title":"Ophthalmologica"},{"key":"R20-6-20210208","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1097\/00061198-200004000-00002","article-title":"Large diurnal fluctuations in intraocular pressure are an independent risk factor in patients with glaucoma","volume":"9","author":"Asrani","year":"2000","journal-title":"J Glaucoma"},{"key":"R21-6-20210208","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1016\/j.ophtha.2004.02.017","article-title":"Predictive factors for glaucomatous visual field progression in the Advanced Glaucoma Intervention Study","volume":"111","author":"Nouri-Mahdavi","year":"2004","journal-title":"Ophthalmology"},{"key":"R22-6-20210208","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/S0002-9394(00)00538-9","article-title":"The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. The AGIS Investigators","volume":"130","year":"2000","journal-title":"Am J Ophthalmol"},{"issue":"suppl","key":"R23-6-20210208","first-page":"U451","article-title":"Blurred vision alter instillation of brinzolamid enad dorzoamide","volume":"45","author":"Ishibashi","year":"2004","journal-title":"Invest Opthalmol Vis Sci"},{"key":"R24-6-20210208","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1016\/S0149-2918(03)80074-7","article-title":"Patient persistency with ocular prostaglandin therapy: a population-based, retrospective study","volume":"25","author":"Reardon","year":"2003","journal-title":"Clin Ther"},{"key":"R25-6-20210208","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.ajo.2005.04.051","article-title":"Persistence and adherence with topical glaucoma therapy","volume":"140","author":"Nordstrom","year":"2005","journal-title":"Am J Ophthalmol"},{"key":"R26-6-20210208","first-page":"190","article-title":"Medication adherence in glaucoma: approaches for optimizing patient compliance","volume":"17","author":"Tsai","year":"2006","journal-title":"Curr Opin Ophthalmol"},{"key":"R27-6-20210208","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1001\/archopht.1994.01090230051020","article-title":"Adverse effects of topical antiglaucoma medication. I. The conjunctival cell profile","volume":"112","author":"Broadway","year":"1994","journal-title":"Arch Ophthalmol"},{"key":"R28-6-20210208","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1097\/01.ico.0000116526.57227.82","article-title":"Corneal and conjunctival changes caused by commonly used glaucoma medications","volume":"23","author":"Noecker","year":"2004","journal-title":"Cornea"},{"key":"R29-6-20210208","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1136\/bjo.86.4.418","article-title":"Prevalence of ocular symptoms and signs with preserved and preservative free glaucoma medication","volume":"86","author":"Pisella","year":"2002","journal-title":"Br J Ophthalmol"},{"key":"R30-6-20210208","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1001\/archopht.1994.01090230060021","article-title":"Adverse effects of topical antiglaucoma medication II. The outcome of filtration surgery","volume":"112","author":"Broadway","year":"1994","journal-title":"Arch Ophthalmol"},{"key":"R31-6-20210208","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1001\/archopht.1990.01070130045027","article-title":"The influence of prior therapy on the success of trabeculectomy","volume":"108","author":"Lavin","year":"1990","journal-title":"Arch Ophthalmol"}],"container-title":["Journal of Glaucoma"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.lww.com\/00061198-200904000-00006","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,13]],"date-time":"2021-04-13T01:56:40Z","timestamp":1618279000000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00061198-200904000-00006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,4]]},"references-count":29,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2009]]}},"URL":"https:\/\/doi.org\/10.1097\/ijg.0b013e31818fb434","relation":{},"ISSN":["1057-0829"],"issn-type":[{"value":"1057-0829","type":"print"}],"subject":[],"published":{"date-parts":[[2009,4]]}}}